Xu G C, Gao R L, Wu Y L
Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997 Jul;17(7):414-6.
To observe the effects of Tongxinluo capsule (TXLC) in treating angina pectoris (AP) caused by coronary heart disease (CHD) and evaluate its safety.
Randomized single-blind controlled design were adopted. Three hundred and forty two patients were treated with TXLC (4 capsules, three times daily), and 150 patients in the control group done with Shuxin oral liquor (SXOL, 20 ml, two times daily). After 4 weeks of treatment, the data of AP, ECG, main symptoms, total effects were collected and evaluated.
TXLC appeared to be more effective than SXOL for patients with mild, moderate, severe AP (P < 0.01), except with mild stomach discomfort for a few patients, TXLC has no side effect and toxicity.
TXLC is an effective drug in treating AP and has no side effects and toxicity.
观察通心络胶囊（TXLC）治疗冠心病（CHD）所致心绞痛（AP）的疗效并评估其安全性。
采用随机单盲对照设计。342例患者接受通心络胶囊治疗（4粒，每日3次），150例对照组患者服用舒心口服液（SXOL，20 ml，每日2次）。治疗4周后，收集并评估心绞痛、心电图、主要症状、总疗效的数据。
对于轻度、中度、重度心绞痛患者，通心络胶囊似乎比舒心口服液更有效（P < 0.01），除少数患者有轻度胃部不适外，通心络胶囊无副作用和毒性。
通心络胶囊是治疗心绞痛的有效药物，且无副作用和毒性。
